ATE425770T1 - Kontrastmittel - Google Patents

Kontrastmittel

Info

Publication number
ATE425770T1
ATE425770T1 AT04701136T AT04701136T ATE425770T1 AT E425770 T1 ATE425770 T1 AT E425770T1 AT 04701136 T AT04701136 T AT 04701136T AT 04701136 T AT04701136 T AT 04701136T AT E425770 T1 ATE425770 T1 AT E425770T1
Authority
AT
Austria
Prior art keywords
contrast agents
formula
moiety
angiotensin
affinity
Prior art date
Application number
AT04701136T
Other languages
English (en)
Inventor
Magne Solbakken
Torgrim Engell
Harry John Wadsworth
Colin M Archer
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Application granted granted Critical
Publication of ATE425770T1 publication Critical patent/ATE425770T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
AT04701136T 2003-01-09 2004-01-09 Kontrastmittel ATE425770T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20030115A NO20030115D0 (no) 2003-01-09 2003-01-09 Kontrastmiddel

Publications (1)

Publication Number Publication Date
ATE425770T1 true ATE425770T1 (de) 2009-04-15

Family

ID=19914362

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04701136T ATE425770T1 (de) 2003-01-09 2004-01-09 Kontrastmittel

Country Status (8)

Country Link
US (1) US7919071B2 (de)
EP (1) EP1581262B1 (de)
JP (1) JP2006517539A (de)
CN (1) CN1723043A (de)
AT (1) ATE425770T1 (de)
DE (1) DE602004020049D1 (de)
NO (1) NO20030115D0 (de)
WO (1) WO2004062568A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
JP2007512321A (ja) * 2003-11-24 2007-05-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
US7763234B2 (en) 2004-03-04 2010-07-27 Ge Healthcare As Pharmaceutical compounds
FR2902428B1 (fr) * 2006-06-15 2008-08-15 Servier Lab Nouveaux derives diazeniumdiolates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2082598B1 (de) * 2006-11-13 2018-04-18 Telefonaktiebolaget LM Ericsson (publ) Drahtlose telekommunikationssysteme
CA2671564A1 (en) * 2006-12-11 2008-06-19 Ge Healthcare As Radiolabelled peptide based compounds and uses thereof
TW201215388A (en) * 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2019134765A1 (en) 2018-01-08 2019-07-11 Julius-Maximilians-Universitaet Wuerzburg Sartan analogue

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0365378A (ja) * 1989-08-04 1991-03-20 Tokyo Tatsuno Co Ltd 複写伝票
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
JPH09165378A (ja) 1995-12-15 1997-06-24 Seitai Kinou Kenkyusho:Kk Ｎ１−［１８ｆ］フルオロベンジル複素環化合物およびそれらの製造法
WO1998018496A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
EP1272507B1 (de) * 2000-04-12 2005-06-29 Amersham Health AS Integrinbindende peptidderivate
WO2001092283A2 (en) * 2000-05-31 2001-12-06 Mayo Foundation For Medical Education And Research Cobalamin compounds useful as cardiovascular agents and as imaging agents
GB0031592D0 (en) * 2000-12-28 2001-02-07 Nycomed Amersham Plc Stabilised radiopharmaceutical compositions
GB0105224D0 (en) * 2001-03-02 2001-04-18 Nycomed Amersham Plc Improved peptide-chelate conjugates
JP4510444B2 (ja) * 2001-07-10 2010-07-21 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチドベースの化合物
GB0116815D0 (en) 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates

Also Published As

Publication number Publication date
EP1581262B1 (de) 2009-03-18
US7919071B2 (en) 2011-04-05
NO20030115D0 (no) 2003-01-09
WO2004062568A2 (en) 2004-07-29
US20070020176A1 (en) 2007-01-25
CN1723043A (zh) 2006-01-18
JP2006517539A (ja) 2006-07-27
DE602004020049D1 (de) 2009-04-30
EP1581262A2 (de) 2005-10-05
WO2004062568A3 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
MXPA04000173A (es) Compuestos basados en peptidos.
NO20073039L (no) Kontrastmidler
ATE425770T1 (de) Kontrastmittel
SG149895A1 (en) Contrast agents for myocardial perfusion imaging
DK1272507T3 (da) Integrinbindende peptidderivater
WO2003105757A3 (en) METHODS AND COMPOSITIONS FOR MEDIA-DEPENDENT BINDING OF A TARGET AGENT TO A TARGET
ATE439868T1 (de) Targetingmittel für molekulare bilderzeugung
IL173029A0 (en) Imaging agents
ATE314097T1 (de) Kontrastmittel
BR0308090A (pt) conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
WO1998018497A3 (en) Contrast agents
HUP0301835A2 (hu) Kationos diagnosztikai, képalkotó és terápiás ágensek, aktivált vaszkuláris helyekkel asszociálódva
DE602005024279D1 (de) 5-substituierte-2-phenylaminobenzamide als mek-inhibitoren
GB0326546D0 (en) Inhibitor imaging agents
ATE376428T1 (de) Metallkomplexverbindungen
WO2007064661A3 (en) Bifunctional metal chelating conjugates
ATE310736T1 (de) Verbindungen zur bilddarstellung der alzheimer- krankenheit
NO20033115D0 (no) Peptid-baserte forbindelser
ATE480552T1 (de) Stq-peptide
WO2005049095A3 (en) Contrast agent imaging angiotensin ii receptors
ITMI20031790A1 (it) Antagonistici abiotici dell'eparina.
DK1485090T3 (da) Kombinationer omfattende et epothilonderivat og en imidazotetrazinon
HN2002000112A (es) Sal citrato de 5, 8,14 - triazatetraciclo [10.3.1.02.11.04.9] - hexadeca - 2 (11),3,5,7,9 - pentaeno y composiciones farmaceuticas de la misma.
TW200628170A (en) Contrast agents for myocardial perfusion imaging

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties